Between 2001-2017, nearly half of all persons in the VA healthcare system were initiated on anti-hepatitis C virus (HCV) treatment, according to a recent study. Researchers examined results from ERCHIVES to determine trends in treatment uptake and provider specialty for HCV infection in the VA healthcare system. Researchers found:
- 108,133 persons (45.7% of diagnosed cases) were initiated on anti-HCV treatment in the VA healthcare system during the study period.
- In 2017, non-MD clinicians accounted for 22.2% of prescriptions, infectious disease specialists for 14.9%, and gastroenterologists/hepatologists for 10.3%.
- In the pre-direct acting antiviral (DAA) ear, they accounted for 7.2%, 26.7%, and 11.6%, respectively.
Butt AA, Yan P, Lo Re V 3rd, Shaikh OS, Ross DB. Trends in treatment uptake and provider specialty for HCV infection in the VA healthcare system: Results from ERCHIVES. [Published online ahead of print August 22, 2018]. Clin Infect Dis. doi:10.1093/cid/ciy697.
Must Reads in Hepatitis
Glecaprevir/Pibrentasvir Efficacy & Safety Assessed, J Hepatol; ePub 2018 Nov 23; D’Ambrosio, et al
HCV Infection Among Children & Young Persons, J Hepatol; ePub 2018 Nov 26; Modin, et al
HCV Patients with Limited Access to Antiviral Therapy, Dig Liver Dis; ePub 2018 Nov 29; Lens, et al
Progression in the Elimination of HCV Infection, PLoS One; ePub 2018 Dec 4; Juanbeltz, et al
Increased HCV Screening in Veteran Populations, Jt Comm J Qual Patient Saf; ePub 2018 Sep 25; Wray, et al